Next Article in Journal
Impact of Digestive Inflammatory Environment and Genipin Crosslinking on Immunomodulatory Capacity of Injectable Musculoskeletal Tissue Scaffold
Next Article in Special Issue
Maternal Low-Grade Chronic Inflammation and Intrauterine Programming of Health and Disease
Previous Article in Journal
Visualization of Chromatin in the Yeast Nucleus and Nucleolus Using Hyperosmotic Shock
Previous Article in Special Issue
Does microRNA Perturbation Control the Mechanisms Linking Obesity and Diabetes? Implications for Cardiovascular Risk
Review

Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance

1
Department of Endocrinology and Nutrition, Institute of Biomedical Research Institute in Malaga (IBIMA), Virgen de la Victoria University Hospital, 29010 Málaga, Spain
2
Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, 14004 Córdoba, Spain
3
CIBEROBN (CIBER in Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Lucia La Sala
Int. J. Mol. Sci. 2021, 22(3), 1133; https://doi.org/10.3390/ijms22031133
Received: 17 December 2020 / Revised: 13 January 2021 / Accepted: 21 January 2021 / Published: 24 January 2021
Evidence from observational and in vitro studies suggests that insulin growth-factor-binding protein type 2 (IGFBP2) is a promising protein in non-communicable diseases, such as obesity, insulin resistance, metabolic syndrome, or type 2 diabetes. Accordingly, great efforts have been carried out to explore the role of IGFBP2 in obesity state and insulin-related diseases, which it is typically found decreased. However, the physiological pathways have not been explored yet, and the relevance of IGFBP2 as an important pathway integrator of metabolic disorders is still unknown. Here, we review and discuss the molecular structure of IGFBP2 as the first element of regulating the expression of IGFBP2. We highlight an update of the association between low serum IGFBP2 and an increased risk of obesity, type 2 diabetes, metabolic syndrome, and low insulin sensitivity. We hypothesize mechanisms of IGFBP2 on the development of obesity and insulin resistance in an insulin-independent manner, which meant that could be evaluated as a therapeutic target. Finally, we cover the most interesting lifestyle modifications that regulate IGFBP2, since lifestyle factors (diet and/or physical activity) are associated with important variations in serum IGFBP2. View Full-Text
Keywords: IGFBP2; obesity; insulin resistance; lifestyle modification; epigenetic IGFBP2; obesity; insulin resistance; lifestyle modification; epigenetic
Show Figures

Figure 1

MDPI and ACS Style

Boughanem, H.; Yubero-Serrano, E.M.; López-Miranda, J.; Tinahones, F.J.; Macias-Gonzalez, M. Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance. Int. J. Mol. Sci. 2021, 22, 1133. https://doi.org/10.3390/ijms22031133

AMA Style

Boughanem H, Yubero-Serrano EM, López-Miranda J, Tinahones FJ, Macias-Gonzalez M. Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance. International Journal of Molecular Sciences. 2021; 22(3):1133. https://doi.org/10.3390/ijms22031133

Chicago/Turabian Style

Boughanem, Hatim, Elena M. Yubero-Serrano, José López-Miranda, Francisco J. Tinahones, and Manuel Macias-Gonzalez. 2021. "Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance" International Journal of Molecular Sciences 22, no. 3: 1133. https://doi.org/10.3390/ijms22031133

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop